
Louis Navellier and the InvestorPlace Research Staff
An icon among growth stock investors
About Louis Navellier and the InvestorPlace Research Staff
Louis Navellier is one of Wall Street’s renowned growth investors. Providing investment advice to tens of thousands of investors for more than three decades, he has earned a reputation as a savvy stock picker and unrivaled portfolio manager.
Over his 35-year investing career, Louis Navellier has established one of the most exceptional long-term track records of any financial newsletter editor in America, and he offers a wide range of simple yet powerful tools that can help all investors to significantly beat the market.
His popular Growth Investor advisory service, established in 1998, has beaten the S&P 500 by a margin of 3-to-1 over the past 17 years.
Navellier continues to build on those stellar records, and while his methodology is rigorous and complex, his goal has been simple, and has been so from the beginning: to uncover Wall Street’s inconsistencies and help investors beat the market with less risk in the market’s best growth stocks. Today, he helps individual investors across the nation and across the globe achieve their financial dreams through his unique newsletter services.
The New York Times called Mr. Navellier “an icon among growth stock investors,” and the media frequently turns to Louis for his expert opinion. He appears regularly on CNBC and Fox Business News and is frequently quoted by MarketWatch, Bloomberg and The Wall Street Journal.
Navellier is an accomplished Wall Street insider as well. He and his team of more than 50 professional analysts and staff manage over $5 billion in mutual funds and institutional accounts through his fund management company, Navellier & Associates.
Louis Navellier also travels the country hosting free seminars for individual investors, and is the author of The Little Book That Makes You Rich, named one of the Top 10 Investing Books of 2007 by SFO Magazine.

Join Louis Navellier’s Market 360 — FREE!
Get Louis Navellier’s take on the news and events impacting the market, plus his top stock picks.
Premium Services
Louis Navellier’s Growth Investor provides an expert’s take on the latest market trends and opportunities. Then Louis shares his picks of High-Growth Investments and Elite Dividend Payers — complete with volatility ratings and buy-below prices.
-
Stocks (Mid- to Large-Cap)
-
Conservative
-
Monthly trades
Already a member? Login here
If you want growth, you’ve got to look at smaller up-and-comers that aren’t as well-known... yet. Louis Navellier’s Breakthrough Stocks lets you participate in high-quality small-caps — according to your personal risk tolerance.
-
Stocks (Small to Mid-Cap)
-
Moderate to Aggressive
-
Monthly trades
Already a member? Login here
Accelerated Profits uses Louis Navellier’s proprietary stock-rating system to identify High Velocity and Ultimate Growth Trades. By combining the “one-two punch” of strong momentum and fundamentals with a more frequent trading schedule, you get significant returns... in a fraction of the time.
-
Stocks (Large-Cap)
-
Aggressive
-
Weekly trades
Already a member? Login here
Louis Navellier’s Platinum Growth combines the top-notch investing strategies of Growth Investor and Breakthrough Stocks with the faster pace of Accelerated Profits — all in a powerful new way that could improve your results 10-fold or better.
-
Stocks
-
Conservative to Aggressive
-
Weekly and monthly trades
Already a member? Login here
Recent Articles
How Another Breakthrough Will Boost NVIDIA Stock
NVDA stock should get a boost from the company's rollout of upgraded GeForce RTX 2080 Super and RTX 2070 Super graphic processing units.
Testing-Kit Clearance Is the Green Light to Buy Co-Diagnostics
A fresh FDA approval means that CODX stock has full permission to clear its previous high mark.
Put Blue Apron Stock in Your Portfolio as Demand for Meal Kits Soars
You can add APRN stock to your holdings as the "new normal" of stay-at-home sticks around, driving a sizable increase in demand.
Gilead Sciences Pins Its Hopes on Remdesivir
Clinical trial results for Gilead's remdesivir should come this month. If it's effective, GILD stock could explode higher on the news.
Customer Loyalty Will Boost Costco Stock After Virus Woes Fade
Even after the hoarding craze subsides, Costco stock should continue to generate strong returns. That makes it a solid stock to buy.